Climb Bio (CLYM) Competitors $2.12 -0.07 (-3.20%) As of 10:25 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLYM vs. ARVN, ANAB, ESPR, OLMA, IVA, ARCT, KOD, CMPX, CMPS, and AQSTShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Arvinas (ARVN), AnaptysBio (ANAB), Esperion Therapeutics (ESPR), Olema Pharmaceuticals (OLMA), Inventiva (IVA), Arcturus Therapeutics (ARCT), Kodiak Sciences (KOD), Compass Therapeutics (CMPX), COMPASS Pathways (CMPS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Arvinas AnaptysBio Esperion Therapeutics Olema Pharmaceuticals Inventiva Arcturus Therapeutics Kodiak Sciences Compass Therapeutics COMPASS Pathways Aquestive Therapeutics Climb Bio (NASDAQ:CLYM) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do institutionals and insiders have more ownership in CLYM or ARVN? 69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 0.8% of Climb Bio shares are owned by insiders. Comparatively, 4.7% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor CLYM or ARVN? In the previous week, Arvinas had 18 more articles in the media than Climb Bio. MarketBeat recorded 24 mentions for Arvinas and 6 mentions for Climb Bio. Arvinas' average media sentiment score of 0.27 beat Climb Bio's score of 0.12 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, CLYM or ARVN? Climb Bio has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$73.90M-$0.70-3.03Arvinas$372.80M1.52-$198.90M-$1.01-7.62 Do analysts prefer CLYM or ARVN? Climb Bio currently has a consensus price target of $9.00, indicating a potential upside of 324.53%. Arvinas has a consensus price target of $16.18, indicating a potential upside of 110.18%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Climb Bio is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Arvinas 0 Sell rating(s) 11 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.55 Which has more volatility and risk, CLYM or ARVN? Climb Bio has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500. Is CLYM or ARVN more profitable? Climb Bio has a net margin of 0.00% compared to Arvinas' net margin of -19.47%. Arvinas' return on equity of -12.01% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -23.10% -22.47% Arvinas -19.47%-12.01%-6.97% SummaryArvinas beats Climb Bio on 9 of the 16 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.66M$3.11B$5.70B$10.23BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-3.0320.6376.0426.13Price / SalesN/A387.65516.68165.77Price / CashN/A45.9137.5661.52Price / Book0.679.7612.676.32Net Income-$73.90M-$52.73M$3.29B$270.94M7 Day Performance-5.36%0.63%0.09%-0.10%1 Month Performance-14.52%6.30%4.14%6.37%1 Year PerformanceN/A18.52%65.69%28.45% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio3.506 of 5 stars$2.12-3.2%$9.00+324.5%N/A$143.66MN/A-3.039Positive NewsAnalyst ForecastARVNArvinas3.3268 of 5 stars$7.72+1.4%$17.13+121.9%-68.7%$558.71M$372.80M-7.64420News CoverageAnalyst DowngradeInsider TradeBuyback AnnouncementHigh Trading VolumeANABAnaptysBio2.3048 of 5 stars$21.08+6.4%$46.13+118.8%-36.5%$554.62M$91.28M-4.71100Positive NewsESPREsperion Therapeutics4.071 of 5 stars$2.75+1.1%$7.00+154.5%+47.3%$548.41M$332.31M-5.61200Gap DownOLMAOlema Pharmaceuticals2.606 of 5 stars$8.51+9.8%$24.00+182.0%-33.8%$531.92MN/A-4.3070IVAInventiva3.1072 of 5 stars$5.42+2.7%$14.83+173.7%+153.2%$518.49M$9.20M0.00100Gap UpARCTArcturus Therapeutics2.8089 of 5 stars$19.62+8.7%$50.57+157.8%-5.9%$490.14M$152.31M-8.80180Gap UpHigh Trading VolumeKODKodiak Sciences2.842 of 5 stars$9.84+6.8%$11.75+19.4%+493.5%$486.49MN/A-2.5990News CoverageAnalyst ForecastCMPXCompass Therapeutics2.684 of 5 stars$3.68+4.8%$13.88+277.0%+104.1%$485.37M$850K-8.1820Positive NewsCMPSCOMPASS Pathways2.9733 of 5 stars$5.08+0.8%$16.29+220.6%-20.4%$483.54MN/A-2.76120Positive NewsAQSTAquestive Therapeutics2.0447 of 5 stars$4.94+2.3%$10.29+108.2%+7.5%$481.67M$44.13M-7.06160 Related Companies and Tools Related Companies Arvinas Competitors AnaptysBio Competitors Esperion Therapeutics Competitors Olema Pharmaceuticals Competitors Inventiva Competitors Arcturus Therapeutics Competitors Kodiak Sciences Competitors Compass Therapeutics Competitors COMPASS Pathways Competitors Aquestive Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
